Current treatment algorithms consider TP53 and IGHV mutational status and patient’s fitness for choosing the best personalized therapeutic approach (7); however, CLL is a heterogeneous group of B cell lymphoma, with various clinical, phenotypic, cytogenetics, and molecular characteristics, affecting clinical outcomes (8). This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.